Update on Loan Agreement
The Directors of Angelfish announce the following update on the convertible loan of £150,000 (“the “Loan”) to Rapid Nutrition Plc (“Rapid”) entered into in
Rapid is a natural healthcare company focused on research, development and production of a range of life science and nutraceutical products. Rapid was established based on its successful and proven nutraceutical supplement range which is exported worldwide and offers consumers a growing range of health and well-being solutions to meet existing and emerging societal health concerns. Rapid is presently listed on the
The terms of the Loan stated that should Admission not occur by
Due to matters outside of Rapid’s control, the Admission process has taken longer than anticipated. In recognition of this, Angelfish has agreed to change the Admission Delay Date from
In addition, Angelfish has agreed that provided Admission occurs on or before
All other aspects of the Loan Agreement remain the same.
This announcement contains information which, prior to its disclosure, was inside information for the purposes of Article 7 of EU Regulation 596/2014.
The directors of the Company take responsibility for this announcement.
NEX Exchange Corporate Adviser
The Company’s Ordinary Shares and Preference Shares are admitted to trading on the NEX Exchange Growth Market in